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ABSTRACT 
Objective: Methotrexate (MTX) is used as an anti-tumor agent, and its clinical pharmacokinetics requires an accurate method for estimation of its 
plasma concentration. We describe a rapid, selective and sensitive HPLC method coupled with UV detection for determination of MTX in rat plasma. 
Methods: Internal standard (IS; caffeine) was added to plasma aliquots prior to protein precipitation with acetonitrile. MTX and IS were eluted on a 
Phenomenex C18 column (250 mm × 4.6 mm, 5 μm) protected by a guard column (4 mm × 3 mm ×5 μm) (Torrance, CA, USA). The mobile phase comprised a 
mixture of aqueous 0.01 M phosphate buffer (pH 3.9)/acetonitrile (89/11%, v/v). To further improve the applicability of the method, a marketed 
formulation of high dose MTX (Folitrax 10 mg, IPCA) was spiked in rat plasma and the developed method was applied for the detection of MTX. 
Results: Adequate specificity, precision, and accuracy of the proposed method were demonstrated over the concentration range of 10 to 1000 ng/ml.  
Conclusion: This developed method was more sensitive and specific than any reported methods for the estimation of MTX and hence was 
successfully applied to measure plasma MTX concentrations in rat plasma which can be useful to elucidate the pharmacokinetic data of MTX.  
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INTRODUCTION 
MTX is a conventional anti-metabolite drug and forms a major part 
of many cancer treatment regimens [1]. It acts by inhibiting folic 
acid, which is essential for DNA synthesis and hence is 
therapeutically effective on cancer cells expressing folate receptors 
on their surfaces [2]. MTX is prominently employed as a 
chemotherapeutic agent for human malignancies such as acute 
lymphoblastic leukemia, malignant lymphoma, osteosarcoma, breast 
cancer and head and neck cancer [3]. MTX is also used as an 
immunosuppressive medication for the therapeutic management of 
inflammatory diseases such as rheumatoid arthritis, acute psoriasis 
and uveitis [4]. MTX can be taken orally or administered by injection 
(subcutaneous, intramuscular, intravenous or intrathecal) [5]. 
However, the usefulness of MTX is greatly hindered by the toxicities 
associated with the drug due to which monitoring the plasma 
concentrations would help to quantify the drug and be valuable to 
predict and prevent the probable toxicity of drug [4]. 
Literature survey revealed that numerous methods for estimation of 
methotrexate have been reported which include HPLC analysis with 
ultraviolet detection and fluorescence detection, radioimmunoassay, 
dihydrofolate reductase inhibition assay, enzyme multiplied 
immunoassay, fluorescence polarization immunoassay, enzyme 
immunoassay and capillary zone electrophoresis with laser–induced 
fluorescence detection [4]. For our purposes, HPLC approaches 
provide the greatest compromise between sensitivity, selectivity, 
assay time and assay expense as the aim of the research was also to 
improve the industrial or commercial applicability of the method. 
Further, there are several HPLC assays, some which are suitable for 
use after high doses such as those used for cancer treatment [5-10]. 
However, these methods have not been established in an animal 
model such as rat plasma. 
Joseph P. Balthasar et al. has also described a high-performance liquid 
chromatographic assay for MTX in the presence and absence of anti-
methotrexate antibody fragments in rat and mouse plasma. However, 
the method involves the pre-column derivatization of MTX by sodium 
hydrosulfite and detection by fluorescence detector which becomes 
multiple steps, time-consuming and less economical [11]. 
In our survey to find a sensitive HPLC assay, we found that the assay 
reported by Eftihia Asprodini et al. appeared most useful. This HPLC 
involved monitoring of MTX in Osteosarcoma Patients. The method 
reported a Limit of Quantitation (LOQ) of 0.01 µM and the Limit of 
Detection (LOD) was 0.003 µΜ [12]. However when we applied the 
method to the analysis of MTX in rat plasma we observed lower 
sensitivity. Further, we also tested the suitability of the method for 
industrial adaptation by spiking the rat plasma with the samples of a 
marketed formulation Folitrax tab 10 mg (IPCA laboratories). We 
have, however, successfully modified the method of Eftihia 
Asprodini et al. for our purposes. 
Hence, in this paper, we describe a simple, economical and convenient 
HPLC procedure with UV detection and simple sample preparation for 
determination of MTX in rat plasma samples which has not been 
effectively tried out. The method is also applied to a marketed 
formulation to improve the industrial applicability of the method. The 
other objective was to validate the assay as per the International 
Conference on Harmonization (ICH) guidelines [Q2 (R1)]. 
MATERIALS AND METHODS 
Materials 
MTX was obtained as a kind gift sample from Machen Product India Pvt. 
Ltd. (Mumbai). Caffeine was supplied by Himedia (Mumbai, India). The 
purity of both the compounds was found to be more than 99%. HPLC 
grade acetonitrile was purchased from SD fine-chem limited (Mumbai, 
India). Other chemicals used were HPLC and analytical grade. Water 
used for the preparation of aqueous mobile phase in all experiments was 
processed through a Milli-Q water purification system supplied by 
Millipore (Bangalore, Karnataka, India) filtered through a 0.22 μm filter. 
Rat blood was collected from healthy male Wistar rats (200–250 g). 
Experimental 
Equipment 
A Shimadzu (Japan) HPLC LC-2010 HT equipped with a Serial dual 
plunger, microvolume (10μL on the primary side, 5μL on secondary) 
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and autosampler was used for the chromatographic separation. 
Phenomenex C18 column (250 mm × 4.6 mm, 5 μm) protected by a 
guard column (4 mm × 3 mm ×5 μm) (Torrance, CA, USA) was 
employed for the analysis. The detection was carried out with the 
UV-Visible SPDM20A detector. LC solutions software was used for 
the interpretation of the results. 
Separation of plasma from rat blood 
Rat plasma was collected from healthy male Wistar rats (200–250 
g), which were fasted overnight before blood collection with free 
access to water. The animals were subjected to acclimatization to 
laboratory conditions one week before experiments and fed with 
standard rat diet. The animals were kept under controlled 
conditions of a 12: 12 h light: dark cycle, with a temperature of 
22±3ºC and a relative humidity of 50±5%RH. Rat blood was 
collected from the retro-orbital plexus by micro capillary technique 
under light ether anesthesia and taken into 3 ml coated vacutainer 
tubes and centrifuged at 10, 000 rpm for 10 min using cold 
centrifuge (Remi Model TC 650 D) to extract the plasma. The plasma 
was stored in deep freeze at–4 °C until further analysis. 
Chromatography 
Chromatographic separations were performed on Shimadzu (Japan) 
HPLC LC-2010 HT PhenomenexC18 column (250 mm × 4.6 mm, 5 μm) 
maintained at 30 ◦C, using a thermostatically controlled column 
heater. The mobile phase comprised a mixture of aqueous 0.01 M 
phosphate buffer (pH 3.9)/acetonitrile (89/11%, v/v) and the pH was 
adjusted to 3.9 with glacial acetic acid (HPLC grade). The flow rate was 
set at 1.0 mL/min. The mobile phase was degassed by ultrasonication 
prior to use. The UV detection wavelength was set at 303 nm. 
Preparation of standard solutions 
A standard stock solution (1 mg/ml) of MTX was prepared in 0.05M 
sodium hydroxide (NaOH). Primary working standard solution (10 
µg/ml) we prepared by serial dilution of the standard stock solution 
with the mobile phase. A stock solution (1 mg/ml) of IS was 
prepared by accurately weighing an appropriate amount of caffeine 
and dissolving it in the mobile phase. Working standard solutions 
(10 µg/ml) were prepared by making appropriate serial dilutions of 
the IS stock solution in the mobile phase. The standard solutions 
were stored at −15 ◦C to −25 ◦C, protected from light and were used 
within seven days. 
Plasma sample extraction and processing 
150μl of drug-free plasma was spiked with MTX and IS by adding 
150μl of the caffeine solution and 150μl of the MTX solution to the 
plasma. The final concentration of IS was set to 1.0 μg/ml. After the 
addition of 150μl of acetonitrile as precipitating agent to the drug-
spiked plasma, the solutions were vortex-mixed for 1 minute 
followed by centrifugation at 15,000 rpm for 15 min using a cold 
centrifuge Remi Model TC 650 D. The supernatant organic layer 
(200 μl) was separated and 50 μl aliquot was injected onto the 
chromatographic system for analysis [12]. 
Preparation of calibration standards and quality control 
samples 
Calibration curve (CC) was prepared by serial dilution of MTX stock 
solution (10g/ml) in the range of 10, 20, 30, 40, 50, 100, 200, 400, 
600, 800 and 1000ng/ml. Similarly, five standard solutions were 
prepared by serial dilution of MTX stock solution (10 g/ml) in the 
range of 1, 2, 3, 4 and 5ng/ml in order to determine the LOD and LOQ. 
Calibration standards were also prepared by spiking 150L of blank 
plasma with 150L of the appropriate working solution resulting in 
concentrations of 10, 20, 30, 40, 50, 100, 200, 400, 600, 800 and 
1000ng/ml and 1, 2, 3, 4 and 5ng/ml of MTX. Stock solution (1g/ml) 
of I. S was prepared in mobile phase and stored at −20ᵒC. The solutions 
were stable for seven days when stored at room temperature (20–
25ᵒC). All solutions were used within one week. Quality control (QC) 
samples (low quality control (LQC),100 ng/ml; medium quality control 
(MQC), 1000 ng/ml; high quality control (HQC), 2500ng/ml; limit of 
quantification (LOQ), 5 ng/ml were prepared by spiking 0.15 mL 
aliquot of blank plasma with 150 L of spiking solution of drug as well 
as the IS. All solutions were stored in the refrigerator at 4.0±2.0∘C. The 
bulk spiked CC and QC samples were stored at −20∘C and brought to 
room temperature before use [12]. 
Validation of the developed method 
All the validation studies were carried out as per ICH guidelines [Q2 
(R1)] by six consecutive replicate injections of the standard and 
sample solutions. Selectivity is a tool to determine the ability of the 
analytical method to differentiate and quantify the analyte in the 
presence of some components expected in the sample. Sensitivity was 
determined by analyzing control rat plasma in replicates (n = 6) 
spiked with the analyte at the lowest level of the calibration standard, 
that is 0.010 μg/ml. Accuracy and precision of the quality control (QC) 
samples were assessed using the calibration curve. Assay precision 
was quantified by expressing the standard deviation of the 
measurements as a percentage of the average value. The accuracy was 
determined for each spiked control by comparing the nominal. 
Extraction recovery 
The recovery of MTX and IS were determined. The recovery of MTX 
was determined at a concentration of 10, 100 and 1000 ng/ml and 
for IS was determined at a concentration of 1000ng/ml. Six 
replicates at each concentration level with peak area response from 
non-extracted control samples prepared at the same concentration 
level were prepared and injected into the HPLC system. 
Precision and accuracy 
The intra-assay precision and accuracy were estimated by analyzing 
six replicates containing MTX at three different levels, i.e., 10, 100 
and 1000 ng/ml. The inter-assay precision was determined by 
analyzing the three levels on six different runs. The criteria for 
acceptability of the data included accuracy within±15% Deviation 
(DEV) from the nominal values and precision within 15% Relative 
Standard Deviation (RSD). For intra-day, accuracy and precision at 
each concentration were assayed on the same day. The inter-day 
accuracy and precision were evaluated for three subsequent days 
[14, 15]. 
LOD and LOQ 
The LOD and LOQ were determined at 3.3 and 10 times the baseline 
noise, respectively [13]. 
Ruggedness 
From the stock solution, sample solutions of MTX (10ng/ml, 
100ng/ml, 500ng/ml and 1000ng/ml) were equipped and analyzed 
by two different analysts employing analogous operational and 
environmental surroundings. The peak area was calculated for 
identical concentration solutions six times. 
Estimation of MTX marketed formulation spiked in rat plasma 
To further improve the applicability of the method, a marketed 
formulation of high dose MTX (Folitrax 10 mg, IPCA) was spiked in 
rat plasma and the developed method was applied for the detection 
of MTX. Standard stock solution (1 mg/ml) of Folitrax was prepared 
in 0.05 M NaOH solution and subsequent dilutions with mobile 
phase were carried out to obtain a concentration (100ng/ml). The 
final sample was prepared as described in the previous section. 
RESULTS AND DISCUSSION 
High-performance liquid chromatography method development 
and optimization 
Column chemistry, solvent type, solvent strength, detection 
wavelength, and flow rate were varied to determine the 
chromatographic conditions with an aim of greater sensitivity and 
separation. The mobile phase conditions were optimized for the 
purpose of minimizing any background noise. After trying different 
columns, the selection was narrowed down to the reversed phase 
Phenomenex C18 column of stationary phase giving satisfactory 
sensitivity, resolution and retention time. Mobile phase and flow 
rate selection was based on peak parameters viz., area, height, 




Short elution time, good separation between MTX
with low background noise were achieved by using a reversed phase 
Phenomenex C18 column with low carbon load. 
research was the selection of the pH of phosphate buffer and alter
 
Fig. 2: HPLC chromatogram of rat
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The absolute recovery of MTX from plasma was calculated by comparing 
the peak area obtained from extracts of spiked plasma samples with
peak area obtained from the direct injection of
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Precision and accuracy 
The precision and accuracy data for the analytical procedures are 
shown in table 2. Intra-day and inter-day precision (%
methods were lower than 14% and were within the acceptable
limits to be in concurrence with the guidelines for United States 
Pharmacopeial (USP) norms method validation which 
to be within 15% (RSD).[15-17] The accuracy of both the methods 
was also good with the deviation between the nominal 
concentration and calculated concentration for 
limits of±15%. Precision and accuracy data indicated 
methods to extract MTX from plasma and tissues are highly 
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Table 3: Values of ruggedness studies for the developed method







Detection of methotrexate in plasma samples
The developed method was found suitable for the detection of MTX
marketed formulation (Folitrax 10 mg) in the 
gave a sharp peak at 7.04 min with a good resolution. The outcome 
of the study was that no interfering peaks of any of the excipients 
were observed as shown in fig. 4. Hence, the presently developed 
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: Recovery of MTX and IS from spiked rat samples 
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is considered 
MTX well below the 
that the 
reproducible and robust. The values 
acceptable in view of the international recommendation that the 
precision and accuracy should not exceed 15% 
Ruggedness 
Two different analysts performed the same analysis under the same 
experimental conditions. The contents of the drug were not greatly 
affected by these changes as obvious from the low values of % RSD 
(2%), indicating ruggedness of the method as shown in table 3
%RSD values of less than 2% were acquired for repetitive 
measurements and operators. 





Inter-day Intra-day Inter-day 
7.07+0.41 6.46 5.86 
 113+5.51 3.97 4.87 
 1062.5+6.25 0.58 1.03 
= 6 d for interday precision). 
 
 amount found%+SD %RSD Analyst 2 amount found%
 5.86 7.10+0.20 
 4.87 113+5.89 
 0.7 512.16+4.62 
9.19 1.03 1066.33+7.71 
 
 
plasma sample. MTX 
method has the potential of detecting MTX
which is an important animal model for preclinical studies. 
the method also has applicability
formulation in the presence of rat plasma which makes the method 
more applicable to study the pharmacokinetics of drug using
an animal model which has not been described in the previously 
described HPLC methods. 
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A simple and sensitive method for the determination of MTX, a 
chemotherapeutic agent, in spiked rat plasma by HPLC was developed 
and validated. Protein precipitation method was employed for sample 
preparation followed by chromatographic separation and UV 
detection. No interfering peaks were observed at the elution times of 
MTX and IS. Adequate specificity, precision, and accuracy of the 
proposed method were demonstrated over the concentration range of 
10 to 1000 ng/ml. The method was accurate, reproducible, specific, 
and provided excellent separation and enable the quantification of 
MTX in rat plasma. The study was also extrapolated for determination 
of MTX in tablet formulation which would improve the industrial 
applicability as well as detection of MTX levels after administering the 
chemotherapeutic dose of the drug. 
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